Clinical Trial

Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an investigator-initiated, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Erythrocyte-αPD-1 conjugates in patients with advanced malignancies
Trial Details
NCT Number NCT06528249
Lead Sponsor Zhejiang Provincial People's Hospital
Collaborators: Westlake Therapeutics
Conditions Cancer, Solid Tumor, Hematologic Malignancy
Enrollment 39 participants
Start Date 2024-07-31
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-30